Leap Therapeutics and BeiGene announce exclusive option and license agreement for DKN-01

This article was originally published here

Leap will retain exclusive rights for the development, manufacturing, and commercialization of DKN-01 for the rest of the world. In addition, Leap announced entering into an agreement for

The post Leap Therapeutics and BeiGene announce exclusive option and license agreement for DKN-01 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply